Condition (MeSH)
Photophobia
ClinicalTrials.gov lists 42 trials for Photophobia or a narrower condition beneath it. Pfizer has the most among industry and government lead sponsors, with 8.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
42 of the 42 trials are tagged with Photophobia itself; the rest are tagged with a narrower condition beneath it.
When did Photophobia trials start? (18)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 1 |
| 2024 | 2 |
| 2023 | 3 |
| 2022 | 2 |
| 2021 | 4 |
| 2020 | 4 |
| 2019 | 4 |
| 2018 | 4 |
| 2016 | 2 |
Showing 10 of 18 earlier years.
No forecast is made for this condition: it averages 2.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 7 trials still running at the 2026-10-09 snapshot; registered median of 20 months across 24 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Photophobia trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1/2 | 2 |
| Phase 2 | 1 |
| Phase 2/3 | 2 |
| Phase 3 | 6 |
| Phase 4 | 1 |
| Not applicable | 25 |
| Observational | 4 |
| Expanded access | 1 |
How many Photophobia trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 9 |
| Completed | 18 |
| Terminated | 5 |
| Withdrawn | 3 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Photophobia trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Pfizer | 8 |
| Achelios Therapeutics | 1 |
| CENTOGENE GmbH Rostock | 1 |
| Laboratórios Baldacci S.A | 1 |
| National Human Genome Research Institute (NHGRI) | 1 |
Which drugs are being tested for Photophobia? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Zavegepant | 3 |
| Rimegepant | 1 |
| Nitisinone | 1 |
Interventions as named in the registry (7)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Rimegepant/BHV3000 | 4 |
| 0.01% concentration atropine drops | 1 |
| Erenumab PFS | 1 |
| Lithium Carbonate Pill | 1 |
| fMRI | 1 |
Showing 5 of 7 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Photophobia trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| COVID-19 | 2 | 1 |
| Cholecystitis | 2 | 1 |
| Hypertensive heart disease | 2 | 1 |
| Iron deficiency anaemia | 2 | 1 |
| Abortion spontaneous | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Photophobia? (44)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Targeting the intrinsically photosensitive retinal ganglion cell to reduce headache pain and light sensitivity in migraine: A randomized double-blind trial. | Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia | 2023 | Yes |
| Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial. | BMC neurology | 2022 | Yes |
| Avoid or seek light - a randomized crossover fMRI study investigating opposing treatment strategies for photophobia in migraine. | The journal of headache and pain | 2022 | Yes |
| Tolerance to Light of Patients Suffering From Infectious Keratitis. | Cornea | 2021 | Yes |
| A randomized study of IV prochlorperazine plus diphenhydramine versus IV hydromorphone for migraine-associated symptoms: A post hoc analysis. | Headache | 2021 | Yes |
Showing 5 of 44 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.